BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singal DP, Ye M, Qiu X. Molecular basis for lack of expression of HLA class I antigens in human small-cell lung carcinoma cell lines. Int J Cancer 1996;68:629-36. [DOI: 10.1002/(sici)1097-0215(19961127)68:5<629::aid-ijc13>3.0.co;2-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Thomas A, Giaccone G. Why has active immunotherapy not worked in lung cancer? Ann Oncol 2015;26:2213-20. [PMID: 26232492 DOI: 10.1093/annonc/mdv323] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
2 Zhou Y, Shi X, Chen H, Mao B, Song X, Gao L, Zhang J, Yang Y, Zhang H, Wang G, Zhuang W. Tumor Immune Microenvironment Characterization of Primary Lung Adenocarcinoma and Lymph Node Metastases. Biomed Res Int 2021;2021:5557649. [PMID: 34337026 DOI: 10.1155/2021/5557649] [Reference Citation Analysis]
3 Jadus MR, Natividad J, Mai A, Ouyang Y, Lambrecht N, Szabo S, Ge L, Hoa N, Dacosta-Iyer MG. Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin Dev Immunol 2012;2012:160724. [PMID: 22899945 DOI: 10.1155/2012/160724] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
4 Brahmer JR. Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? Semin Oncol 2014;41:126-32. [PMID: 24565586 DOI: 10.1053/j.seminoncol.2013.12.014] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
5 Boyle LH, Goodall JC, Gaston JS. Major histocompatibility complex class I-restricted alloreactive CD4+ T cells. Immunology 2004;112:54-63. [PMID: 15096184 DOI: 10.1111/j.1365-2567.2004.01857.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]